Most Popular Stories
- House Democrats To Ditch Permanent Estate Tax Bill For 1-Year Fix
- UPDATE: Reckitt May Be Close To Merger With Colgate -Report
- US Industry Groups Urge Multi-Year Highway-Spending Bill
- Sources: Reckitt May Be Close To Merger With Colgate-Palmolive Report
- Petrobras Energy Sells Argentina Fertilizer Unit To Bunge
Latest News Q&A
NASDAQ Answers allows you to pose questions to our community of investors. Can you answer this one?
GlaxoSmithKline, Valeant File Retigabine New Drug ApplicationLONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare company, and Valeant Pharmaceuticals International (VRX) said Monday that, on Oct. 30, they filed a new drug application with the U.S. Food and Drug Administration and a marketing authorisation application with the European Medicines Agency, for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures. MAIN FACTS: -Retigabine is not approved or licensed anywhere in the world. -By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com (END) Dow Jones Newswires 11-02-090843ET Copyright (c) 2009 Dow Jones & Company, Inc. |
 Click here for a free trial |
